Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells

Onkologie

Volumn 28, Issue 4, 2005, Pages 209-215

  Campbell, Stephanie A ^a   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Conditional replication; Receptor; Tropism; Viruses, oncolytic

Indexed keywords

ACICLOVIR; CELL RECEPTOR; GANCICLOVIR; NEWCASTLE DISEASE VACCINE; ONCOLYTIC VIRUS; ONYX 015; VIRUS PROTEIN; VIRUS RECEPTOR;

ADENOVIRUS; CANCER CELL; CANCER CELL DESTRUCTION; CANCER THERAPY; CELL DAMAGE; CELL KILLING; COXSACKIE VIRUS 21; COXSACKIE VIRUS A; COXSACKIE VIRUS A15; DNA VIRUS; GENE DELETION; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS 1; HUMAN; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PICORNAVIRUS; POLIOMYELITIS VIRUS; REOVIRUS; REVIEW; RNA VIRUS; TRANSCRIPTION REGULATION; TUMOR CELL; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; METHODOLOGY; NEOPLASM; NOTE; VIROLOGY; VIRUS;

ANIMALS; GENE DELETION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; NEOPLASMS; RECEPTORS, VIRUS; VIRUS REPLICATION; VIRUSES;

EID: 20844445104     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084010     Document Type: Review

References (89)

1. Campbell SA, Gromeier M: Oncolytic viruses for cancer therapy I: cell-external factors: Virus entry and receptor interaction. Onkologie 2005;28:144-149.
2. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
3. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, Vernon CC, Gueret-Wardle D, El-Masry R, Salama H, Ahmed R, Michail N, Edward E, Jensen SL: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2000;12:219-226.
4. Reid TR, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D: Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity. Proc Am Soc Clin Oncol 2001;20:549a.
5. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D: Safety and feasibility of injection with an E1B-55kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 2001;8:308-315.
6. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM: A prospective phase II trial of ONYX-015 adnovirus and chomterhapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-592.
7. Nemunaitis J, Khuri E, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-298.
8. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competenet adenovirus (ARCA) CN706: A selective cytotoxic for prostate-sepcific antigen-positite prostate cancer cells. Cancer Res 1997;2559-2563.
9. Yu D, Chen Y, Seng M, Dilley J, Henderson DR: The addition of adenovirus type 5 region E3 enables Calydon virus 787 to elijminate distant prostate tumor xenografts. Cancer Res 1999;59:4200-4203.
10. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61:517-525.
11. Kurihara T, Brough DE, Kovesdi I, Kufe DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-771.
12. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, Phipps S, Chiang YL: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-1733.
13. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-856.
14. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994;54:3936-3936.
15. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996;93:11313-11318.
16. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL: Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000;6:3342-3353.
17. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
18. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000;7:867-874.
19. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y: Oncolytic viral therapy for human colorectral cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-1334.
20. Toda M, Rabkin SD, Martuza RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-2185.
21. Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999;1:162-169.
22. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-2243.
23. Meignier B, Martin B, Whitley RJ, Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162:313-321.
24. Meignier B, Longnecker R, Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-614.
25. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y: Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000;4:580-588.
26. Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, Johnson P, Scardino PT, Heston WD, Fong Y: Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001;15:1306-1308.
27. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y: Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12-21.
28. Miyatake S, Iyer A, Martuza RL, Rabkin SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997;71:5124-5132.
29. Miyatake S, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD: Hepatoma-specific anti-tumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999;6:564-572.
30. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-422.
31. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-8757.
32. Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I: Antitumor effect of vaccinia virus in glioma model. Oncol Res 1999;11:133-144.
33. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-1334.
34. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-825.
35. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000;97:6803-6808.
36. Shafren ER, Au GG, Barry G: Therapeutic application of coxsackievirus A15 and A21 as novel oncolytic anti-tumour agents for control of malignant human melanoma (abstract no. K8). Europic2002. 2002 May 13-19; Falmouth, MA, 431.
37. Cassel WA, Garrett RE: Newcastle disease virus as an anti-neoplastic agent. Cancer 1965;18:863-868.
38. Csatary LK, Bakacs T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999;281:1588-1589.
39. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-2266.
40. Muller U, Steinnoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M: Functional role of type I and II interferons in antiviral defense. Science 1994;264:1918-1921.
41. Dreiding P, Staeheli P, Haller O: Interferon-induced protein Mx accumulates in nuclei of mouse cells expressing resistance to influenza viruses. Virology 1985;140:192-196.
42. Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C: Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 1986;44:147-158.
43. Chebath J, Benech P, Revel M, Vigneron M: Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 1987;330:587-588.
44. Zaragoza C, Ocampo C, Saura M, Leppo M, Wei XQ, Quick R, Moncada S, Liew FY, Lowenstein CJ: The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci USA 1998;95:2469-2474.
45. Der SD, Lau AS: Involvement of the double-stranded-RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity. Proc Natl Acad Sci USA 1995;92:8841-8845.
46. Colamonici OR, Domanski P, Platanias LC, Diaz MO: Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood 1992;80:744-749.
47. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272:28779-28785.
48. Abril E, Mendez RE, Garcia A, Serrano A, Cabrera T, Garrido F, Ruiz-Cabello F: Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens 1996;47:391-398.
49. Samuel CE: Reoviruses and the interferon system. Current Topics Microbiol Immunol 1998;233:125-145.
50. Duncan MR, Stanish WM, Cox DC: Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978;28:444-449.
51. Hashiro G, Loh PC, Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307-315.
52. Strong, JE, Coffey, MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-3362.
53. Belkowski LS, Sen, GC: Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J Virol 1987;61:653-660.
54. Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC: The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 2000;74:9580-9585.
55. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN: Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000;13:129-141.
56. Balachandran S, Porosnicu M, Barber GN: Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001;75:3474-3479.
57. Levaditi C, Haber P: Affinité du virus de la peste aviaire pour les cellules neoplastiques. Compt Rend Soc Biol 1936;202:2018-2020.
58. Sinkovics JG, Horvath JC: Newcastle disease virus (NDV): Brief history of its oncolytic strains. J Clin Virol 2000;16:1-15.
59. Roberts MS, Buasen PT, Incao BA, et al.: PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts. Proc Am Assoc Cancer Res 2001;42:2441a.
60. Lorence RM, Roberts MS, Groene WS, et al.: Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. Proc Am Assoc Cancer Res 2001;42:2442a.
61. Tenser RB, Miller RL, Rapp F: Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science 1979;205:915-917.
62. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM: Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 1989;86:4736-4740.
63. Goldstein DJ, Weller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988;62:196-205.
64. Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B: Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 1993;91:2837-2843.
65. Chou J, Kern ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262-1266.
66. Chou J, Roizman B: The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992;89:3266-3270.
67. Chou J, Chen JJ, Gross M, Roizman B: Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIE-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995;92:10516-10520.
68. Gale M, Katze MG: Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998;78:29-46.
69. Taneja S, MacGregor J, Markus S, Ha S, Mohr I: Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001;98:8804-8808.
70. Mohr I, Gluzman Y: A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996;15:4759-4766.
71. Mulvey M, Poppers J, Ladd A, Mohr I: A herpes-virus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. J Virol 1999;73:3375-3385.
72. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y: A herpes simplex virus type 1 gamma 34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001;75:5189-5196.
73. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813-815.
74. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B: Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988;62:866-874.
75. Flint J, Schenk T: Viral transactivating proteins. Annu Rev Genet 1997;31:177-212.
76. De Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998;12:2434-2442.
77. Miyashita T, Reed JC: Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-299.
78. Yew PR, Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992;357:82-85.
79. Yew PR, Liu X, Berk AJ: Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev 1994;8:190-202.
80. Kao CC, Yew PR, Berk AJ: Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990;179:806-814.
81. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL: The large E1B protein together with E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 1998;16:349-357.
82. Dix BR, Edwards SJ, Braithwaite AW: Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001;75:5443-5447.
83. Goodrum FD, Ornelles DA: p53 status does not determine outcome of E1b 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-9490.
84. Harada JN, Berk AJ: p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73:5333-5344.
85. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998;72:9470-9478.
86. Turnell AS, Grand RJA, Gallimore H: The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999;73:2074-2083.
87. Koch P, Gatfield J, Lober C, Hobom U, Lenz-Stoppler C, Roth J, Dobbelstein M: Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. Cancer Res 2001;61:5941-5947.
88. Jackson RJ, Kaminski A: Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond. RNA 1995;1:985-1000.
89. Gromeier M, Alexander L, Wimmer E: Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 1996;93:2370-2375.